No risk ... no reward
I’d like to see the treatments turn into something, but not at a cost of risking value to share holders.
The commentary from patients using the treatment (non-placebo) on the study was positive. From what I recall the results were on par with an American peer although with a very small sample size, testing safety not cure. Upping dosage could prove to lift above the competition. The American along with the global population has seen the disease rise in recent years
Main concern I have is that it didn’t seem like Wayne explained the results well from the last immunotherapy test.
No risk ... no reward I’d like to see the treatments turn into...
-
- There are more pages in this discussion • 364 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
-0.300(1.64%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.29 | $18.30 | $17.65 | $181.7K | 10.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 30 | $17.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.00 | 499 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |